Cargando…
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
The epidermal growth factor receptor (EGFR) is one of most potent oncogenes that are commonly altered in cancers. As a receptor tyrosine kinase, EGFR's kinase activity has been serving as the primary target for developing cancer therapeutics, namely the EGFR inhibitors including small molecules...
Autores principales: | Thomas, Rintu, Weihua, Zhang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716122/ https://www.ncbi.nlm.nih.gov/pubmed/31508364 http://dx.doi.org/10.3389/fonc.2019.00800 |
Ejemplares similares
-
Kinase-Inactivated EGFR Is Required for the Survival of Wild-Type EGFR-Expressing Cancer Cells Treated with Tyrosine Kinase Inhibitors
por: Thomas, Rintu, et al.
Publicado: (2019) -
Rethinking the Initial Board Certification Exam
por: Greenky, David, et al.
Publicado: (2021) -
EGFR/FOXO3A/LXR-α Axis Promotes Prostate Cancer Proliferation and Metastasis and Dual-Targeting LXR-α/EGFR Shows Synthetic Lethality
por: Chen, Tingting, et al.
Publicado: (2020) -
Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023) -
Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer
por: Ni, Rui, et al.
Publicado: (2023)